ClinicalTrials.gov
public full text
Public Domain
A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Conditions
The purpose of this study is to compare the relative bioavailability of 800 mg Gabapentin Tablets by Purepac Pharmaceutical Co. with that of 400 mg (2 x 400 mg) NEURONTIN® by Parke-Davis under fasting conditions.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Non-fasting Conditions#868116
- Bioequivalence Study of Gabapentin 400 mg Capsules Under Fed Conditions#136257
- An Open Label Pharmacokinetic Study Of Gabapentin In Japanese Subjects With Renal Impairment Including Hemodialysis#811893
- A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Non-fasting Conditions#882054
- Gabapentin for Sleep in Critically Ill Patients#1137388
Record · ID 1033663
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive